A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia
Anemia is a condition characterized by a deficiency of red blood cells (RBCs) or hemoglobin (Hb), resulting in a diminished capacity of the blood to carry and deliver oxygen to tissues and organs (Abbasi et al., 2014). Anemia is often multifactorial in etiology and may be patient- (e.g., iron-deficiencies, vitamin deficiencies), disease- (e.g., bone marrow diseases, chronic diseases, hemorrhage), or anticancer treatment- (e.g., chemotherapy, radiotherapy, precision therapies) related (Crathorne et al., 2016).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Luiz H. Arantes, Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte, Jay Wish Source Type: research
More News: Anemia | Cancer & Oncology | Chemotherapy | Chronic Kidney Disease | Hematology | Iron | Urology & Nephrology | Vitamins